BRPI0808503B8 - composto, uso de um composto, e, composição farmacêutica - Google Patents

composto, uso de um composto, e, composição farmacêutica

Info

Publication number
BRPI0808503B8
BRPI0808503B8 BRPI0808503A BRPI0808503A BRPI0808503B8 BR PI0808503 B8 BRPI0808503 B8 BR PI0808503B8 BR PI0808503 A BRPI0808503 A BR PI0808503A BR PI0808503 A BRPI0808503 A BR PI0808503A BR PI0808503 B8 BRPI0808503 B8 BR PI0808503B8
Authority
BR
Brazil
Prior art keywords
compound
relates
alzheimer
disease
compositions
Prior art date
Application number
BRPI0808503A
Other languages
English (en)
Portuguese (pt)
Inventor
Swahn Britt-Marie
Wensbo David
Arzel Erwan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0808503A2 publication Critical patent/BRPI0808503A2/pt
Publication of BRPI0808503B1 publication Critical patent/BRPI0808503B1/pt
Publication of BRPI0808503B8 publication Critical patent/BRPI0808503B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
BRPI0808503A 2007-03-06 2008-03-05 composto, uso de um composto, e, composição farmacêutica BRPI0808503B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89314907P 2007-03-06 2007-03-06
US60/893149 2007-03-06
US60/893,149 2007-03-06
PCT/SE2008/050243 WO2008108730A1 (en) 2007-03-06 2008-03-05 Novel 2-heteroaryl substituted benzothiophenes and benzofuranes 709

Publications (3)

Publication Number Publication Date
BRPI0808503A2 BRPI0808503A2 (pt) 2014-08-19
BRPI0808503B1 BRPI0808503B1 (pt) 2020-09-29
BRPI0808503B8 true BRPI0808503B8 (pt) 2021-05-25

Family

ID=39738510

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808503A BRPI0808503B8 (pt) 2007-03-06 2008-03-05 composto, uso de um composto, e, composição farmacêutica

Country Status (23)

Country Link
US (1) US7772256B2 (enExample)
EP (1) EP2132201B1 (enExample)
JP (1) JP5631009B2 (enExample)
KR (1) KR101530392B1 (enExample)
CN (2) CN102617556A (enExample)
AR (1) AR065599A1 (enExample)
AU (1) AU2008221668B2 (enExample)
BR (1) BRPI0808503B8 (enExample)
CA (1) CA2680157C (enExample)
CL (1) CL2008000645A1 (enExample)
CO (1) CO6220965A2 (enExample)
EC (1) ECSP099641A (enExample)
ES (1) ES2615381T3 (enExample)
IL (1) IL200524A0 (enExample)
MX (1) MX2009009469A (enExample)
MY (1) MY147347A (enExample)
NZ (1) NZ579157A (enExample)
PE (1) PE20090164A1 (enExample)
SA (1) SA08290097B1 (enExample)
TW (1) TW200901998A (enExample)
UA (1) UA98481C2 (enExample)
UY (1) UY30951A1 (enExample)
WO (1) WO2008108730A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
EP2300481B1 (en) 2008-05-30 2015-09-30 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
BRPI0917540A2 (pt) 2008-08-05 2015-11-17 Daiichi Sankyo Co Ltd composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
EP2388255A1 (en) * 2010-05-11 2011-11-23 Ikerchem, S.L. Polysubstituted benzofurans and medicinal applications thereof
JP5825608B2 (ja) * 2010-08-06 2015-12-02 国立大学法人京都大学 ピリジルベンゾフラン誘導体
MX2020008082A (es) * 2018-02-05 2020-09-24 Univ Strasbourg Compuestos y composiciones para el tratamiento del dolor.
BR112021026837A2 (pt) * 2019-08-06 2022-02-22 Domain Therapeutics Compostos de 5-heteroaril-piridin-2-amina como anta-gonistas do receptor de neuropeptídeo ff

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU523040B2 (en) 1978-05-15 1982-07-08 Kanebo Limited Calcium -antagonistic composition
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
CA2034309C (en) 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
CA2176127A1 (en) * 1993-12-21 1995-06-29 William Henry Walker Lunn Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
US5518713A (en) 1995-02-13 1996-05-21 3V Inc. Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them
JPH11116476A (ja) 1997-10-16 1999-04-27 Sankyo Co Ltd 縮合複素環化合物
SI1334091T1 (sl) 2000-08-24 2013-01-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Derivati tioflavina in njihova uporaba pri diagnozi in terapiji pri Alzheimerjevi bolezni
JP2004524289A (ja) 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
US20040077654A1 (en) * 2001-01-15 2004-04-22 Bouillot Anne Marie Jeanne Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
JP4307001B2 (ja) * 2001-03-14 2009-08-05 キヤノン株式会社 金属配位化合物、電界発光素子及び表示装置
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
KR20040058111A (ko) 2001-04-23 2004-07-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 아밀로이드 플라크 응집 억제제 및 진단 영상화제
EP1460067A4 (en) 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
AU2003242233A1 (en) 2002-06-12 2003-12-31 Bf Research Institute, Inc. Probe compound for image diagnosis of disease with amyloid accumulation, compound for staining age spots/diffuse age spots, and remedy for disease with amyloid accumulation
TW200401194A (en) 2002-07-11 2004-01-16 Advanced Micro Devices Inc Method and apparatus for determining a processor state without interrupting processor operation
ATE425753T1 (de) 2002-08-02 2009-04-15 Genesoft Pharmaceuticals Inc Biaryl-verbindungen mit antiinfektiver wirkung
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
JPWO2004087641A1 (ja) 2003-03-31 2006-06-29 第一製薬株式会社 ヒドラゾン誘導体
CN100372844C (zh) 2003-05-13 2008-03-05 弗·哈夫曼-拉罗切有限公司 作为腺苷受体配体的2-咪唑-苯并噻唑
EP1644365A2 (en) * 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2006251832A1 (en) 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
MX2007015675A (es) * 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
WO2007033080A2 (en) 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
WO2007035405A2 (en) 2005-09-16 2007-03-29 University Of Pittsburgh In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein
SI1945622T1 (sl) 2005-10-11 2012-05-31 Univ Pittsburgh Izotopično markirane spojine benzfurana kot označevalne snovi za amiloidogenske proteine
WO2007063946A1 (ja) 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. アミロイドの凝集及び/又は沈着に起因する疾患の診断薬及び治療薬
TW200736252A (en) 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
US7700616B2 (en) 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
EP2125800A1 (en) 2007-01-22 2009-12-02 AstraZeneca AB Novel heteroaryl substituted imidazo ý1,2 -a¨pyridine derivatives
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes

Also Published As

Publication number Publication date
MY147347A (en) 2012-11-30
KR20090117892A (ko) 2009-11-13
IL200524A0 (en) 2010-04-29
CO6220965A2 (es) 2010-11-19
EP2132201A1 (en) 2009-12-16
RU2009133257A (ru) 2011-04-20
AR065599A1 (es) 2009-06-17
CL2008000645A1 (es) 2008-10-24
CN101675042B (zh) 2012-06-13
KR101530392B1 (ko) 2015-06-22
US7772256B2 (en) 2010-08-10
US20080221149A1 (en) 2008-09-11
CA2680157A1 (en) 2008-09-12
TW200901998A (en) 2009-01-16
AU2008221668B2 (en) 2011-03-31
JP2010520276A (ja) 2010-06-10
BRPI0808503B1 (pt) 2020-09-29
WO2008108730A1 (en) 2008-09-12
AU2008221668A1 (en) 2008-09-12
CN102617556A (zh) 2012-08-01
EP2132201A4 (en) 2011-05-25
PE20090164A1 (es) 2009-05-03
UY30951A1 (es) 2008-10-31
EP2132201B1 (en) 2016-11-16
UA98481C2 (en) 2012-05-25
NZ579157A (en) 2012-04-27
ES2615381T3 (es) 2017-06-06
CN101675042A (zh) 2010-03-17
CA2680157C (en) 2016-04-12
JP5631009B2 (ja) 2014-11-26
SA08290097B1 (ar) 2011-10-29
ECSP099641A (es) 2009-10-30
MX2009009469A (es) 2009-09-15
BRPI0808503A2 (pt) 2014-08-19

Similar Documents

Publication Publication Date Title
BRPI0808503B8 (pt) composto, uso de um composto, e, composição farmacêutica
ECSP088645A (es) Nuevos benzotiazoles sustituidos con heteroaril
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
ES2218531T3 (es) Arilalquilaminas activas sobre los receptores del calcio.
WO2009155017A3 (en) Novel substituted azabenzoxazoles
ES2584653T3 (es) Sonda para la obtención de imágenes de Tau
MX2009007487A (es) Derivados de imidazo[1,2-a]piridina substituidos de heteroarilo novedosos.
BR112016028345A2 (pt) composto, composição farmacêutica, métodos para inibir agregação de tau em um mamífero e para avaliar depósitos de tau em um paciente, e, uso de um composto.
BRPI0812504B8 (pt) composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
ES2908949T3 (es) Agentes psicotrópicos y sus usos
ECSP12011857A (es) Compuestos de dióxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso
CR10621A (es) Derivados de adenosina como agonistas del receptor a2a
AR070395A1 (es) Derivados de 4,5-dihidro-oxazol-2-il- amina
GT200900007A (es) Derivados de purina como agonistas de a2a
AR114029A2 (es) Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesos
EA200801529A1 (ru) Кристаллические формы 1-бензоил-4-[2-[4-метокси-7-(3-метил-1h-1,2,4-1-ил)-1-[(фосфонокси)метил]-1h-пирроло[2,3-c]пиридин-3-ил]-1,2-диоксоэтил]пиперазина
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
BRPI0808090A2 (pt) Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
AR068439A1 (es) Derivado de 6-pirimidinil-pirimid-2-ona
BRPI0606321A2 (pt) tetraidropiridinas 3,4,(5)-substituìdas
Hausner et al. Synthesis of 5-and 6-substituted 2-(4-dimethylaminophenyl)-1, 3-benzoxazoles and their in vitro and in vivo evaluation as imaging agents for amyloid plaque
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
BR112021012834A2 (pt) Derivados de pirimidina para a prevenção e tratamento de infecções bacterianas gram-negativas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/03/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF